[go: up one dir, main page]

AU3490300A - Dopamine agonists in combination with nitric oxide donors, compositions and methods of use - Google Patents

Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Info

Publication number
AU3490300A
AU3490300A AU34903/00A AU3490300A AU3490300A AU 3490300 A AU3490300 A AU 3490300A AU 34903/00 A AU34903/00 A AU 34903/00A AU 3490300 A AU3490300 A AU 3490300A AU 3490300 A AU3490300 A AU 3490300A
Authority
AU
Australia
Prior art keywords
compositions
methods
combination
nitric oxide
dopamine agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34903/00A
Inventor
David S. Garvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of AU3490300A publication Critical patent/AU3490300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU34903/00A 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use Abandoned AU3490300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12392099P 1999-03-12 1999-03-12
US60123920 1999-03-12
PCT/US2000/003709 WO2000054773A1 (en) 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Publications (1)

Publication Number Publication Date
AU3490300A true AU3490300A (en) 2000-10-04

Family

ID=22411703

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34903/00A Abandoned AU3490300A (en) 1999-03-12 2000-03-10 Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Country Status (2)

Country Link
AU (1) AU3490300A (en)
WO (1) WO2000054773A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE19938825A1 (en) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Active ingredient combination with clonidine
DE19938823A1 (en) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
NZ522112A (en) * 2000-04-21 2004-10-29 Upjohn Co Substituted phenylazacycloalkane-type compounds for treating fibromyalgia and chronic fatigue syndrome
MXPA03007960A (en) * 2001-03-06 2003-12-04 Cellegy Pharma Inc Compounds and methods for the treatment of urogenital disorders.
ITMI20011308A1 (en) 2001-06-21 2002-12-21 Nicox Sa DRUGS FOR CHRONIC PAIN
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
EP1463440B1 (en) * 2001-12-06 2009-12-02 Duke University Prevention of flap necrosis in plastic surgery
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
ITMI20022658A1 (en) 2002-12-17 2004-06-18 Nicox Sa DRUGS FOR CHRONIC PAIN.
WO2005084660A1 (en) * 2004-03-05 2005-09-15 Morishige, Fumie Prevention and measure for mitochondrial disease
EP2380579A1 (en) * 2004-04-19 2011-10-26 Strategic Science & Technologies, LLC Beneficial effects of increasing local blood flow
ES2429443T3 (en) 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Transdermal supply of beneficial substances by means of an environment of high ionic strength
AU2012201048B2 (en) * 2004-04-19 2013-06-06 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ITMI20041855A1 (en) * 2004-09-29 2004-12-29 Polichem Sa PHARMACEUTICAL COMPOSITIONS OF ALFA-DIHYDROERGOCRIPTINE FOR TRANSDERMAL AND-OR TRANSMUCOUS USE.
WO2010134074A1 (en) 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
EP2445492B1 (en) 2009-06-24 2016-09-28 Strategic Science & Technologies, LLC Topical composition containing ibuprofen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
RS57047B1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
CN103442723A (en) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 Systems and methods for treatment of allergies and other indications
CN104349768B (en) 2012-06-05 2017-11-07 纽罗德姆有限公司 Composition comprising apomorphine and organic acid and application thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
CN105434439B (en) * 2015-11-11 2018-07-24 温州医科大学 A kind of partial agonist of d2 dopamine receptor inhibits the application on near-sighted drug and its application method preparing
US10945980B2 (en) 2016-06-21 2021-03-16 The University Of Newcastle Treatment for myopia
EP3616723B1 (en) * 2018-07-18 2024-08-07 Wenzhou Medical University Use of nicotinic acid or prazosin for treating myopia
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US12194037B2 (en) * 2023-01-06 2025-01-14 Microneb Tech Holdings, Inc. Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
ES2143049T3 (en) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHINE AND ITS USE FOR THE TREATMENT OF ERECTILE DYSFUNCTION.

Also Published As

Publication number Publication date
WO2000054773A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
AU3490300A (en) Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
EP1497268A4 (en) Nitric oxide donors, compositions and methods of use
GB0020259D0 (en) Methods and compositions for use in cementing in cold environments
EE05210B1 (en) Antidiabetic agent and its use in medicine
AU2003243984A1 (en) Hydrogenated copolymer and composition thereof
HUP9900152A3 (en) Anti-microbial cosmetical composition based on alcohol and its use
PL360698A1 (en) Guanidinobenzamides as mc4-r agonists
HK1082194A1 (en) Composition comprising echovirus ev1 and its use ev1
AU2003230715A1 (en) In vivo use of glutathionone s-transferase activated nitric oxide donors
AU2001230902A1 (en) Slow-release insect-repellent composition and uses
TWI349689B (en) Light-curable composition and coating agent composition
AU2002347614A1 (en) Antioxidant combination composition and use thereof
IL144710A0 (en) Methods and compositions for use in perfusion applications
HUP0203844A3 (en) Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use
AU2003251394A1 (en) An oral composition with insulin-like activities and methods of use
AU2002233271A1 (en) Substitued oxazoles and thiazoles as hppar alpha agonists
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
ZA200108318B (en) Cosmetics composition which provides good hold properties and which comprises a copolymer with an acid unit.
AU2001265025A1 (en) Fluorinated copolymer surfactants and use thereof in aerosol compositions
AU2002361337A1 (en) Amphoteric polysaccharide, composition and use
AU7598000A (en) Antimicrobial topical composition and methods
AU3774100A (en) Heat-activated cleaning compositions with wrinkle-resistance and methods of use
AU2185501A (en) Siloxane-based lubricating composition, not releasing hydrogen, preparation method and use thereof
ZA200210123B (en) Preparation with vascular protective and anti-oxidative effect and use thereof.
AU2001232089A1 (en) Compound, composition and use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase